1. Colorectal surgeons' perspectives on the efficacy of intraoperative bowel perfusion technology with a focus on indocyanine green fluorescence angiography.
- Author
-
Singaravelu A, Entee PDM, Boland PA, Moynihan A, McCarrick C, Vahrmeijer AL, Arezzo A, Boni L, Hompes R, and Cahill RA
- Subjects
- Humans, Coloring Agents, Surveys and Questionnaires, Male, Attitude of Health Personnel, Female, Intraoperative Care methods, Colorectal Surgery, Practice Patterns, Physicians', Surgeons, Indocyanine Green, Fluorescein Angiography methods, Anastomotic Leak prevention & control
- Abstract
Background: Level one evidence supports indocyanine green fluorescence angiography (ICGFA) use reducing anastomotic leak rates in colorectal surgery. We surveyed surgeons exploring perceptions and factors affecting its use in daily practice and adoption as routine standard of care., Methods: Validated electronic survey distributed via the Irish Association of Coloproctology, Royal College of Surgeons in Ireland, European Society of Surgical Oncology, European Association for Endoscopic Surgery, Milan Colorectal Congress and social media., Results: 200 colorectal surgeons (143 consultants) responded. 147 (73.5%) surgeons already use ICGFA, with 90 (61.2%) using it routinely and 69 (46.9%) having a concomitant research interest. Strong clinical evidence base (83.5%) and protocol standardisation (78%) were overall rated most important for bowel perfusion technology with a majority of surgeons rating lack of standardisation and inter-user variability as challenges (similar between consultants and non-consultants). Lack of training and staff, reliability concerns and data security were perceived as significant barriers by selective users compared to non-users, and cost and operating time were perceived as significant barriers by selective users compared to routine users. Most surgeons (41.5%) ideated a number needed to treat (NNT) between 20 and 40 acceptable to advocate routine ICGFA use with 28% requiring a NNT < 20. Most surgeons (38.5%) indicate a per case cost savings of €250-500 supports routine use with 17% advocating it > €750., Conclusions: With now a strong evidence base regarding clinical benefit, the survey respondents articulate remaining challenges for ICGFA as standard of care. Levels of expected benefit are largely in keeping with its reported performance., Competing Interests: Declarations. Competing interests: Professor Ronan A Cahill receives speaker fees from Stryker Corp and Ethicon/J&J, consultancy fees from Arthrex, Astellas, Diagnostic Green and Touch Surgery (Medtronic), research funding from Intuitive Corp and Medtronic as well as, recently, from the Irish Government (DTIF) in collaboration with IBM Research in Ireland and from EU Horizon 2020 in collaboration with Palliare and, currently, from Horizon Europe in collaboration with Arctur. Professor Alberto Arezzo receives speaker fees from Karl Storz, Tuttlingen. Professor Luigi Boni receives speaker fees from Ethicon/J&J, Storz and Olympus, consultancy fees from Arthrex, CMR, Storz, Intuitive and Olympus. Mr Ashokkumar Singaravelu, Dr Philip D Mc Entee, Dr Patrick A. Boland, Dr Alice Moynihan, Dr Cathleen McCarrick, Professor Roel Hompes and Professor Alexander L. Vahrmeijer have no conflicts of interest or financial ties to disclose., (© 2025. The Author(s).)
- Published
- 2025
- Full Text
- View/download PDF